E-LIB Suche - Ergebnisse für: Kerbusch, T

1

有多少人开发生物制剂 tildrakizumab 的抗药抗体, 以及这对其治疗有效性产生哪些影响:

Kimball, A.B. ; Kerbusch, T. ; van Aarle, F....
British Journal of Dermatology. 182 (2020) 1 - p. e48-e48 , 2020

Link: https://doi.org/10.1111/..

2

How many people develop anti-drug antibodies to the biologi..:

Kimball, A.B. ; Kerbusch, T. ; van Aarle, F....
British Journal of Dermatology. 182 (2020) 1 - p. e31-e31 , 2020

Link: https://doi.org/10.1111/..

3

Assessment of the effects of immunogenicity on the pharmaco..:

Kimball, A.B. ; Kerbusch, T. ; Aarle, F....
British Journal of Dermatology. 182 (2019) 1 - p. 180-189 , 2019

Link: https://doi.org/10.1111/..

4

Good Practices in Model‐Informed Drug Discovery and Develop..:

EFPIA MID3 Workgroup ; Marshall, SF ; Burghaus, R...
CPT: Pharmacometrics & Systems Pharmacology. 5 (2016) 3 - p. 93-122 , 2016

Link: https://doi.org/10.1002/..

5

Implementation of Quantitative and Systems Pharmacology in ..:

Visser, S A G ; de Alwis, D P ; Kerbusch, T..
CPT: Pharmacometrics & Systems Pharmacology. 3 (2014) 10 - p. 1-10 , 2014

Link: https://doi.org/10.1038/..

6

Prediction of Clinical Irrelevance of PK Differences in Ato..:

Vargo, R ; Adewale, A ; Behm, M O..
Clinical Pharmacology & Therapeutics. 96 (2014) 1 - p. 101-109 , 2014

Link: https://doi.org/10.1038/..

7

Modeling and Simulation at the Interface of Nonclinical and..:

Visser, SAG ; Manolis, E ; Danhof, M.
CPT: Pharmacometrics & Systems Pharmacology. 2 (2013) 2 - p. 1-3 , 2013

Link: https://doi.org/10.1038/..

8

Modeling and Simulation of the Time Course of Asenapine Exp..:

Friberg, LE ; de Greef, R ; Kerbusch, T.
Clinical Pharmacology & Therapeutics. 86 (2009) 1 - p. 84-91 , 2009

Link: https://doi.org/10.1038/..

9

P.3.c.056 Population pharmacokinetics of asenapine in patie..:

Prohn, M. ; De Greef, R. ; Chapel, S..
European Neuropsychopharmacology. 19 (2009) - p. S542-S543 , 2009

Link: https://doi.org/10.1016/..

10

Planning for an adaptive design: a case study in COPD:

Jones, B. ; Atkinson, G. ; Ward, J...
Pharmaceutical Statistics. 5 (2006) 2 - p. 135-144 , 2006

Link: https://doi.org/10.1002/..

11

Distribution of ifosfamide and metabolites between plasma a..:

Kerbusch, T. ; Herben, V.M.M. ; Jeuken, M‐J.J....
Biopharmaceutics & Drug Disposition. 22 (2001) 3 - p. 99-108 , 2001

Link: https://doi.org/10.1002/..

12

Modulation of the cytochrome P450–mediated metabolism of if..:

Kerbusch, T
Clinical Pharmacology & Therapeutics. 70 (2001) 2 - p. 132-141 , 2001

Link: https://doi.org/10.1067/..

13

SIMULTANEOUS DETERMINATION OF IFOSFAMIDE AND ITS METABOLITE..:

Kerbusch, T. ; Huitema, A. D. R. ; Jeuken, M-J. J....
Journal of Liquid Chromatography & Related Technologies. 23 (2000) 19 - p. 2991-3010 , 2000

Link: https://doi.org/10.1081/..

14

HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF TH..:

Huitema, A. D. R. ; Tibben, M. M. ; Kerbusch, T....
Journal of Liquid Chromatography & Related Technologies. 23 (2000) 11 - p. 1725-1744 , 2000

Link: https://doi.org/10.1081/..

15

Evaluation of the autoinduction of ifosfamide metabolism by..:

Kerbusch, T. ; Huitema, A. D. R. ; Ouwerkerk, J....
British Journal of Clinical Pharmacology. 49 (2000) 6 - p. 555-561 , 2000

Link: https://doi.org/10.1046/..